Consolidated Statements of Operations Data

Quarter Ended

March 31

June 30

September 30

December 31

(In thousands, except per share amounts)

2019

Total revenues(1)

$

8,131

$

962

$

8,855

$

422

Operating costs and expenses

(6,195)

(5,673)

(5,964)

(4,423)

Income (loss) from operations

1,936

(4,711)

2,891

(4,001)

Other income (expense), net

1,297

639

287

(320)

Net income (loss) before income tax

3,233

(4,072)

3,178

(4,321)

Income tax (expense) benefit

 —

 —

 —

 —

Net income (loss)

$

3,233

$

(4,072)

$

3,178

$

(4,321)

Basic net income (loss) per share attributable to common stockholders

$

0.22

$

(0.47)

$

0.21

$

(0.49)

Diluted net income (loss) per share attributable to common stockholders (2)

$

0.21

$

(0.47)

$

0.20

$

(0.49)

2018

Total revenues(3)

$

463

$

2,255

$

896

$

1,685

Restructuring (charge) credit

 —

(459)

(909)

(543)

Operating costs and expenses

(5,600)

(4,787)

(5,294)

(4,564)

Loss from operations

(5,137)

(2,991)

(5,307)

(3,422)

Other income, net

1,331

1,044

729

312

Net loss before income tax

(3,806)

(1,947)

(4,578)

(3,110)

Income tax benefit

 —

 —

 —

98

Net loss

$

(3,806)

$

(1,947)

$

(4,578)

$

(3,012)

Basic net loss per share attributable to common stockholders

$

(0.46)

$

(0.23)

$

(0.55)

$

(0.35)

Diluted net loss per share attributable to common stockholders

$

(0.46)

$

(0.23)

$

(0.55)

$

(0.35)

(1)

Total revenues mainly include $14.0 million of revenue recognized in the first and the third quarter in 2019 under the license agreement and common stock purchase agreement with Rezolute, and $2.5 million in milestone revenue earned in the third quarter of 2019 under our license agreement with Janssen.